Regulatory Operations

Carton: 2010-22-521-00-326
Current 5

Lacquer free area:
Lacquerform: 30271-1

Braille No.: XXXX-XX-X
Placement: Front

5 Pcs

Colour:
PMS 280C +
PMS 289C +
Cyan +
Black +
PMS 219C

Code centre line
Code: 100% Direction
Length: Max 29 mm (100%)

2
8

Keep out of the sight and reach of children
Read the package leaflet before use

For use by one person only
Do not withdraw solution from the pen

Use only clear, colourless solution

Before opening: Store in a refrigerator (2°C – 8°C)
During use: Store at a maximum of 30°C or store in a refrigerator. Use within 21 days
Do not freeze
Keep the cap on the pen to protect from light
Recommended for use with NovoTwist® or NovoFine® disposable needles
Discard the needle after each injection

One pre-filled pen contains 300 units insulin degludec and 10.8 mg liraglutide in 3 ml solution
1 ml solution contains 100 units of insulin degludec and 3.6 mg liraglutide, glycerol, phenol 5.70 mg, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections

Jauhkan daripada capaian kanak-kanak
Controlled Medicine/Ubat Terkawal

Product Registration Holder
Novo Nordisk Pharma (M) Sdn Bhd
Menara 1 Sentrum, Level 16
No. 201, Jalan Tun Sambanthan
50470 Kuala Lumpur

© 2018

Manufactured and released by:

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

novo nordisk®

22-521-00

5×3 ml
Xultophy®
100 units/ml + 3.6 mg/ml
solution for injection
insulin degludec + liraglutide

5×3 ml
Xultophy®
100 units/ml + 3.6 mg/ml
solution for injection in pre-filled pen
insulin degludec + liraglutide

Subcutaneous use

MALXXXXXXXXAZ

One Xultophy® dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide

Needles are not included

novo nordisk®

Manuf./Expiry/Batch:

8-9553-00-312-1

5×3 ml
Xultophy®
100 units/ml + 3.6 mg/ml
solution for injection
insulin degludec + liraglutide